Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 5/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25776576 | 1.00 | CASP2 (0.67) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL12791885 | 0.97 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL12792260 | 0.97 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL12903703 | 0.97 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL12792213 | 0.97 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL12792118 | 0.95 | CASP2 (0.69) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL12791914 | 0.95 | CASP2 (0.69) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL12791781 | 0.95 | CASP2 (0.69) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL12903704 | 0.95 | CASP2 (0.69) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL12792210 | 0.95 | CASP2 (0.69) | CASP2NAAAFAAHEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | CASP2 3774/4885NAAA 64/4885FAAH 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.